OKYO Pharma Activates First Clinical Trial Site For Phase 2 Study Of OK-101 To Treat Dry Eye Disease
SponsoredOKYO Pharma Management Takes Company Stock In Private Placement Instead Of Deferred Pay
SponsoredOKYO Pharma To Begin Phase 2 Efficacy Trials For Dry Eye Disease Drug Candidate In Q2 2023, Anticipates Releasing Topline Results In Q4
SponsoredOKYO Pharma's Trial Treating Subjects With DED Gets Listed On ClinicalTrials.gov
SponsoredOKYO Pharma Recent News
OKYO Pharma CEO Gary Jacob Discusses The Company's Future Plans
Sponsored
OKYO Pharma's Drug OK-101 Clears Customs in the US; To Be Used In Phase 2, First-In-Human, Clinical Trial For Patients With Dry Eye Disease
Sponsored
Dry Eye Disease Impacts 49 Million Americans And Disproportionately Affects Women, But Current Treatments Aren't Fully Effective – OKYO Pharma's Drug Candidate Could Be The Solution
Sponsored